A comparison of the antitumour efficacy of ZD6474 and gefitinib (IresSa™) in patients with NSCLC:: Results of a randomized, double-blind Phase II study

被引：27

作者：

Natale, R

Bodkin, D

Govindan, R

Sleckman, B

Rizvi, N

Capo, A

Germonpré, P

Dimery, I

Webster, A

Ranson, M

机构：

[1] Cedars Sinai Outpatient Canc Ctr, Los Angeles, CA USA

[2] Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA

[3] Washington Univ, Sch Med, St Louis, MO USA

[4] St Johns Mercy Med Ctr, St Louis, MO 63141 USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[6] COIR, Mendoza, Argentina

[7] Univ Antwerp Hosp, Antwerp, Belgium

[8] AstraZeneca, Macclesfield, Cheshire, England

[9] Christie Hosp, Manchester, Lancs, England

来源：

关键词：

D O I：

10.1016/S0169-5002(05)80237-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S37 / S37

页数：1